Hereditary features, treatment, and prognosis of the lipoprotein glomerulopathy in patients with the APOE Kyoto mutation

Kidney International

Volumn 85, Issue 2, 2014, Pages 416-424

  Hu, Zhangxue ^a   Huang, Songmin ^a   Wu, Yu ^a,b   Liu, Yunqiang ^a   Liu, Xiaoxia ^a   Su, Dan ^a   Tao, Ye ^a   Fu, Ping ^a   Zhang, Xiuhui ^a   Peng, Ziying ^a   Zhang, Sizhong ^a   Yang, Yuan ^a  

^a SICHUAN UNIVERSITY   (China)

^b KANAZAWA UNIVERSITY   (Japan)

Author keywords

APOE Kyoto; apolipoprotein E; fenofibrate; lipoprotein glomerulopathy

Indexed keywords

ALBUMIN; APOLIPOPROTEIN E; CREATININE; CYCLOPHOSPHAMIDE; FENOFIBRATE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PREDNISONE; TRIACYLGLYCEROL;

ALBUMIN BLOOD LEVEL; APOE GENE; ARTICLE; CHINA; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DNA SEQUENCE; EXON; FAMILY STUDY; FEMALE; GENE; GENE FREQUENCY; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE; GLOMERULOPATHY; HETEROZYGOSITY; HUMAN; HUMAN CELL; LIPOPROTEIN GLOMERULOPATHY; MALE; PEDIGREE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEINURIA; RETROSPECTIVE STUDY; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

ADOLESCENT; ADULT; AGED; APOLIPOPROTEIN E2; BIOLOGICAL MARKERS; BIOPSY; CASE-CONTROL STUDIES; CHINA; CREATININE; DISEASE PROGRESSION; DNA MUTATIONAL ANALYSIS; FEMALE; FENOFIBRATE; GENETIC PREDISPOSITION TO DISEASE; HEREDITY; HUMANS; HYPOLIPIDEMIC AGENTS; KAPLAN-MEIER ESTIMATE; KIDNEY; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MUTATION; PEDIGREE; PHENOTYPE; PROTEINURIA; REMISSION INDUCTION; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; TRIGLYCERIDES; YOUNG ADULT;

EID: 84893338005     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2013.335     Document Type: Article

References (51)

1. Saito T, Sato H, Kudo K et al. Lipoprotein glomerulopathy: Glomerular lipoprotein thrombi in a patient with hyperlipoproteinemia. Am. J. Kidney Dis. 1989; 13: 148-153
2. Watanabe Y, Ozaki I, Yoshida F et al. A case of nephrotic syndrome with glomerular lipoprotein deposition with capillary ballooning and mesangiolysis. Nephron 1989; 51: 265-270
3. Saito T, Matsunaga A, Oikawa S. Impact of lipoprotein glomerulopathy on the relationship between lipids and renal diseases. Am J Kidney Dis 2006; 47: 199-211
4. Sam R, Wu H, Yue L et al. Lipoprotein glomerulopathy: A new apolipoprotein E mutation with enhanced glomerular binding. Am J Kidney Dis 2006; 47: 539-548
5. Rall SC Jr., Weisgraber KH, Mahley RW. Human apolipoprotein E. The complete amino acid sequence. J Biol Chem 1982; 257: 4171-4178
6. Weisgraber KH, Innerarity TL, Mahley RW. Abnormal lipoprotein receptorbinding activity of the human E apoprotein due to cysteine-Arginine interchange at a single site. J Biol Chem 1982; 257: 2518-2521
7. Oikawa S, Matsunaga A, Saito T et al. Apolipoprotein E Sendai (arginine 145-4proline): A new variant associated with lipoprotein glomerulopathy. J Am Soc Nephrol 1997; 8: 820-823
8. Matsunaga A, Sasaki J, Komatsu T et al. A novel apolipoprotein E mutation, E2 (Arg25Cys), in lipoprotein glomerulopathy. Kidney Int 1999; 56: 421-427
9. Luo B, Huang F, Liu Q et al. Identification of Apolipoprotein E Guangzhou (Arginine 150 Proline), a new variant associated with lipoprotein glomerulopathy. Am J Nephrol 2008; 28: 347-352
10. Chen S, Liu Z-H, Zheng J-M et al
11. Zhang B, Liu ZH, Zeng CH et al. Clinicopathological and genetic characteristics in Chinese patients with lipoprotein glomerulopathy. J Nephrol 2008; 21: 110-117
12. Konishi K, Saruta T, Kuramochi S et al. Association of a novel 3-Amino acid deletion mutation of apolipoprotein E (Apo E Tokyo) with lipoprotein glomerulopathy. Nephron 1999; 83: 214-218
13. Ando M, Sasaki J, Hua H et al. A novel 18-Amino acid deletion in apolipoprotein E associated with lipoprotein glomerulopathy. Kidney Int 1999; 56: 1317-1323
14. Murano T, Matsumura R, Misawa Y et al. Interaction of endothelial cells and triglyceride-rich lipoproteins with apolipoprotein E (Arg-4Cys) from a patient with lipoprotein glomerulopathy. Metabolism 2002; 51: 201-205
15. Toyota K, Hashimoto T, Ogino D et al. A founder haplotype of APOESendai mutation associated with lipoprotein glomerulopathy. J Hum Genet 2013; 58: 254-258
16. Foster K, Matsunaga A, Matalon R et al. A rare cause of posttransplantation nephrotic syndrome. Am J Kidney Dis 2005; 45: 1132-1138
17. Rovin BH, Roncone D, McKinley A et al. APOE Kyoto mutation in European Americans with lipoprotein glomerulopathy. N Engl J Med 2007; 357: 2522-2524
18. Arai T, Yamashita S, Yamane M et al. Disappearance of intraglomerular lipoprotein thrombi and marked improvement of nephrotic syndrome by bezafibrate treatment in a patient with lipoprotein glomerulopathy. Atherosclerosis 2003; 169: 293-299
19. Han J, Pan Y, Chen Y et al. Common apolipoprotein E gene mutations contribute to lipoprotein glomerulopathy in China. Nephron Clin Pract 2010; 114: C260-c267
20. Liao MT, Tsai IJ, Cheng HT et al. A rare cause of childhood-onset nephrotic syndrome: Lipoprotein glomerulopathy. Clin Nephrol 2012; 78: 237-240
21. Cheung CY, Chan AO, Chan YH et al. A rare cause of nephrotic syndrome: Lipoprotein glomerulopathy. Hong Kong Med J 2009; 15: 57-60
22. Ito K, Nakashima H, Watanabe M et al. Macrophage impairment produced by Fc receptor gamma deficiency plays a principal role in the development of lipoprotein glomerulopathy in concert with apoE abnormalities. Nephrol Dial Transplant 2012; 27: 3899-3907
23. Miyahara Y, Nishimura S, Watanabe M et al. Scavenger receptor expressions in the kidneys of mice with lipoprotein glomerulopathy. Clin Exp Nephrol 2011; 16: 115-121
24. Tokura T, Itano S, Kobayashi S et al. A novel mutation ApoE2 Kurashiki (R158P) in a patient with lipoprotein glomerulopathy. J Atheroscler Thromb 2011; 18: 536-541
25. Pasquariello A, Pasquariello G, Innocenti M et al. Lipoprotein glomerulopathy: First report of 2 not consanguineous Italian men from the same town. J Nephrol 2011; 24: 381-385
26. Mitani A, Ishigami M, Watase K et al. A novel apolipoprotein E mutation, ApoE Osaka (Arg158 Pro), in a dyslipidemic patient with lipoprotein glomerulopathy. J Atheroscler Thromb 2011; 18: 531-535
27. Hamatani H, Hiromura K, Kobatake K et al. Successful treatment of lipoprotein glomerulopathy in a daughter and a mother using niceritrol. Clin Exp Nephrol 2010; 14: 619-624
28. Boumendjel R, Papari M, Gonzalez M. A rare case of lipoprotein glomerulopathy in a white man: An emerging entity in Asia, rare in the white population. Arch Pathol Lab Med 2010; 134: 279-282
29. Bomback AS, Song H, D'Agati VD et al. A new apolipoprotein E mutation, apoE Las Vegas, in a European-American with lipoprotein glomerulopathy. Nephrol Dial Transplant 2010; 25: 3442-3446
30. Russi G, Furci L, Leonelli M et al. Lipoprotein glomerulopathy treated with LDL-Apheresis (Heparin-induced Extracorporeal Lipoprotein Precipitation system): A case report. J Med Case Reports 2009; 3: 9311
31. Matsunaga A, Furuyama M, Hashimoto T et al. Improvement of nephrotic syndrome by intensive lipid-lowering therapy in a patient with lipoprotein glomerulopathy. Clin Exp Nephrol 2009; 13: 659-662
32. Kinomura M, Sugiyama H, Saito T et al. A novel variant apolipoprotein E Okayama in a patient with lipoprotein glomerulopathy. Nephrol Dial Transplant 2008; 23: 751-756
33. Hagiwara M, Yamagata K, Matsunaga T et al. A novel apolipoprotein E mutation, ApoE Tsukuba (Arg 114 Cys), in lipoprotein glomerulopathy. Nephrol Dial Transplant 2008; 23: 381-384
34. Tsimihodimos V, Elisaf M. Lipoprotein glomerulopathy. Curr Opin Lipidol 2011; 22: 262-269
35. Saito T, Oikawa S, Sato H et al. Lipoprotein glomerulopathy: Renal lipidosis induced by novel apolipoprotein E variants. Nephron 1999; 83: 193-201
36. Xin Z, Zhihong L, Shijun L et al. Successful treatment of patients with lipoprotein glomerulopathy by protein A immunoadsorption: A pilot study. Nephrol Dial Transplant 2009; 24: 864-869
37. Amenomori M, Haneda M, Morikawa J et al. A case of lipoprotein glomerulopathy successfully treated with probucol. Nephron 1994; 67: 109-113
38. Ieiri N, Hotta O, Taguma Y. Resolution of typical lipoprotein glomerulopathy by intensive lipid-lowering therapy. Am J Kidney Dis 2003; 41: 244-249
39. Cramer PE, Cirrito JR, Wesson DW et al. ApoE-directed therapeutics rapidly clear beta-Amyloid and reverse deficits in AD mouse models. Science 2012; 335: 1503-1506
40. Yue L, Mazzone T. Peroxisome proliferator-Activated receptor {gamma} stimulation of adipocyte ApoE gene transcription mediated by the liver receptor X pathway. J Biol Chem 2009; 284: 10453-10461
41. Boerwinkle E, Utermann G. Simultaneous effects of the apolipoprotein E polymorphism on apolipoprotein E, apolipoprotein B, and cholesterol metabolism. Am J Hum Genet 1988; 42: 104-112
42. Saito T, Sato H, Oikawa S et al. Lipoprotein glomerulopathy. Report of a normolipidemic case and review of the literature. Am J Nephrol 1993; 13: 64-68
43. Oikawa S, Suzuki N, Sakuma E et al. Abnormal lipoprotein and apolipoprotein pattern in lipoprotein glomerulopathy. Am J Kidney Dis 1991; 18: 553-558
44. Saito T, Oikawa S, Sato H et al. Lipoprotein glomerulopathy: Significance of lipoprotein and ultrastructural features. Kidney Int Suppl 1999; 71: S37-S41
45. Reiner Z, Catapano AL, De Backer G et al. ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011; 32: 1769-1818
46. Keech A, Simes RJ, Barter P et al. Effects of long-Term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial. Lancet 2005; 366: 1849-1861
47. Hottelart C, El Esper N, Rose F et al. Fenofibrate increases creatininemia by increasing metabolic production of creatinine. Nephron 2002; 92: 536-541
48. Hottelart C, el Esper N, Achard JM et al. [Fenofibrate increases blood creatinine, but does not change the glomerular filtration rate in patients with mild renal insufficiency]. Nephrologie 1999; 20: 41-44
49. Wang L, Shearer GC, Budamagunta MS et al. Proteinuria decreases tissue lipoprotein receptor levels resulting in altered lipoprotein structure and increasing lipid levels. Kidney Int 2012; 82: 990-999
50. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 1990; 31: 545-548
51. Levey AS, Coresh J, Balk E et al. National Kidney Foundation practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Ann Intern Med 2003; 139: 137-147